Hormone Sensitive Breast Cancer is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hormone Sensitive Breast Cancer have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hormone Sensitive Breast Cancer compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hormone Sensitive Breast Cancer overview
Estrogen and progesterone promote the growth of some breast cancers, which are called hormone-sensitive (or hormone-dependent) breast cancers. Hormone-sensitive breast cancer cells contain proteins called hormone receptors (estrogen receptors, or ERs, and progesterone receptors, or PRs) that become activated when hormones bind to them. The activated receptors cause changes in the expression of specific genes, which can stimulate cell growth.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Hormone Sensitive Breast Cancer, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.